Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 406 to 420 of 1037 results for criteria

  1. Irritable bowel syndrome in adults (QS114)

    This quality standard covers diagnosing and managing irritable bowel syndrome in adults. It describes high-quality care in priority areas for improvement.

  2. Developmental follow-up of children and young people born preterm (QS169)

    This quality standard covers the developmental follow-up of babies, children and young people under 18 years who were born preterm (before 37+0 weeks of pregnancy). It describes high-quality care in priority areas for improvement.

  3. The NxStage System One NX1000‑1 home haemodialysis device for renal replacement therapy in chronic kidney disease (MIB12)

    NICE has developed a medtech innovation briefing (MIB) on The NxStage System One NX1000-1 home haemodialysis device for renal replacement therapy in chronic kidney disease .

  4. The PressureWire fractional flow reserve measurement system for coronary artery disease (MIB2)

    NICE has developed a Medtech Innovation Briefing (MIB) on the PressureWire fractional flow reserve measurement system

  5. Erectile dysfunction: avanafil (ESNM45)

    Summary of the evidence on avanafil for treating erectile dysfunction to inform local NHS planning and decision-making

  6. Antimicrobial prescribing: delafloxacin for community-acquired pneumonia (ES37)

    Summary of the evidence on delafloxacin for community-acquired pneumonia in adults

  7. Weight management: lifestyle services for overweight or obese adults (PH53)

    This guideline covers multi-component lifestyle weight management services including programmes, courses, clubs or groups provided by the public, private and voluntary sector. The aim is to help people lose weight and become more physically active to reduce the risk of diseases associated with obesity. This includes coronary heart disease, stroke, type 2 diabetes and various cancers.

  8. Mifamurtide for the treatment of osteosarcoma (TA235)

    Evidence-based recommendations on mifamurtide (Mepact) for treating osteosarcoma in people aged 2 to 30 years.

  9. Cabozantinib for previously treated advanced renal cell carcinoma (TA463)

    Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advance renal cell carcinoma in adults.

  10. Nivolumab for previously treated advanced renal cell carcinoma (TA417)

    Evidence-based recommendations on nivolumab (Opdivo) for previously treated advanced renal cell carcinoma in adults.

  11. Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA770)

    Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for adults with untreated metastatic squamous non-small-cell lung cancer.

  12. NICE real-world evidence framework (ECD9)

    The NICE real-world evidence framework aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence

  13. Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (TA374)

    Evidence-based recommendations on erlotinib (Tarceva) and gefitinib (Iressa) for treating non-small-cell lung cancer after chemotherapy in adults.

  14. Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA387)

    Evidence-based recommendations on abiraterone (Zytiga) for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated in adults.

  15. Commentary - dementia

    in funding over the last few years and as a consequence the eligibility criteria has raised considerably. Families of people with...